LAB
Standard BioTools Inc.
LAB trails on the overall score without a compensating advantage in the available component scores.
LLY
Eli Lilly and Company
LLY has the edge over LAB overall, supported by stronger fundamentals and lower modeled downside.
LAB Fundamentals
| Metric | Status |
|---|---|
| Under pressure | |
| Stable | |
| Under pressure | |
| Unavailable |
LAB's profitability is currently stable, but its revenue and cash flow are under pressure. There isn't enough data to rate its balance sheet.
LLY Fundamentals
| Metric | Status |
|---|---|
| Healthy | |
| Strong | |
| Strong | |
| Healthy |
LLY's revenue, profitability, cash flow and balance sheet are all currently healthy.
LAB PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Current | 1.9x | $0.65 | — |
| Cheap | 2.9x | $0.98 | +51% |
| Fair | 3.6x | $1.21 | +86% |
| Expensive | 4.7x | $1.61 | +147% |
Historical ranges are pointers, not guarantees.
LAB has the edge over LLY in the historical PE scenario, which offers more potential upside but is not a forecast.
LLY PE Valuation
| Level | PE | Price | Vs current |
|---|---|---|---|
| Cheap | 27x | $845 | -41% |
| Forward | 30x | $1,427 | — |
| Current | 46x | $1,427 | — |
| Fair | 48x | $1,466 | +2.7% |
| Expensive | 85x | $2,612 | +83% |
Historical ranges are pointers, not guarantees.
LLY's PE is in its fair range at 46x. If earnings grow as analysts expect, today's price would be 30x next year's earnings, in its cheap range.
LAB Forward outlook
| Metric | Outlook |
|---|---|
| -- | |
| Losses growing | |
| Growth | |
| Strongly weakening | |
| Limited | |
| High |
Analysts expect LAB's losses to grow, with revenue growing.
LLY Forward outlook
| Metric | Outlook |
|---|---|
| Strongly improving | |
| Strong growth | |
| Strong growth | |
| Strongly improving | |
| Limited | |
| Moderate |
LLY has the edge over LAB on the outlook, with more favorable earnings and profitability expectations.
LAB Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Q3 2026 | $0.34 | +$0.65 |
| Q2 2026 | $0.22 | +$0.51 |
| Q1 2026 | $0.20 | +$0.52 |
| Q4 2025 | -$0.20 | +$0.32 |
| Q3 2025 | -$0.31 | +$0.39 |
| Q2 2025 | -$0.29 | +$0.61 |
| Q1 2025 | -$0.32 | +$0.68 |
| Q4 2024 | -$0.52 | +$0.42 |
LAB has returned to profit: it earned $0.34 per share over the past year, after losing money the year before.
LLY Earnings Per Share
| Quarter | TTM EPS | YoY |
|---|---|---|
| Forward | $46.83 | +52% |
| Q3 2026 | $30.81 | +51% |
| Q2 2026 | $29.80 | +95% |
| Q1 2026 | $28.15 | +129% |
| Q4 2025 | $22.95 | +96% |
| Q3 2025 | $20.44 | +121% |
| Q2 2025 | $15.30 | +88% |
| Q1 2025 | $12.29 | +81% |
| Q4 2024 | $11.71 | +102% |
LLY's earnings per share have climbed steadily: $30.81 over the past year, up 51% from the year before, and higher year over year for 11 quarters in a row.
LAB Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $19.4M | -0.9% |
| Q2 2026 | $20.1M | -7.6% |
| Q1 2026 | $21.1M | -48% |
| Q4 2025 | $23.8M | -49% |
| Q3 2025 | $19.6M | -57% |
| Q2 2025 | $21.8M | -42% |
| Q1 2025 | $40.8M | -10% |
| Q4 2024 | $46.7M | +66% |
LAB's revenue has slid since its 2024 peak: $19M last quarter, about level with the same quarter a year ago.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | -102% | +67 points |
| Q2 2026 | -126% | -8.2 points |
| Q1 2026 | -59% | +22 points |
| Q4 2025 | -104% | -33 points |
| Q3 2025 | -168% | -98 points |
| Q2 2025 | -118% | +18 points |
| Q1 2025 | -81% | +51 points |
| Q4 2024 | -70% | +5.6 points |
LAB's operating margin was −102% last quarter, up 66 points from the same quarter a year ago.
LLY Quarterly Revenue
| Quarter | Revenue | YoY |
|---|---|---|
| Q3 2026 | $24.4B | +39% |
| Q2 2026 | $23B | +48% |
| Q1 2026 | $19.8B | +56% |
| Q4 2025 | $19.3B | +43% |
| Q3 2025 | $17.6B | +54% |
| Q2 2025 | $15.6B | +38% |
| Q1 2025 | $12.7B | +45% |
| Q4 2024 | $13.5B | +45% |
LLY has the edge over LAB on sales, with more consistent year-over-year improvement.
| Quarter | Margin | YoY |
|---|---|---|
| Q3 2026 | 34% | -6.6 points |
| Q2 2026 | 40% | -3.3 points |
| Q1 2026 | 45% | +18 points |
| Q4 2025 | 43% | +5.6 points |
| Q3 2025 | 41% | +27 points |
| Q2 2025 | 44% | +12 points |
| Q1 2025 | 27% | -1.8 points |
| Q4 2024 | 37% | +10 points |
LLY has the edge over LAB on profitability, with a higher operating margin.
LAB Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | -$6.2M | +$16.9M |
| Q2 2026 | -$10.7M | +$11.9M |
| Q1 2026 | -$47.2M | -$11.8M |
| Q4 2025 | -$1.7M | +$15.8M |
| Q3 2025 | -$23.1M | +$7M |
| Q2 2025 | -$22.6M | +$18.4M |
| Q1 2025 | -$35.3M | +$27.9M |
| Q4 2024 | -$17.4M | -$3.3M |
LAB has burned cash in almost every quarter: −$66M over the past year, against −$98M the year before.
LLY Free Cash Flow
| Quarter | Free cash flow | YoY |
|---|---|---|
| Q3 2026 | $8.2B | +22% |
| Q2 2026 | $7.8B | +458% |
| Q1 2026 | $3B | +1826% |
| Q4 2025 | $677.9M | -31% |
| Q3 2025 | $6.7B | +186% |
| Q2 2025 | $1.4B | +476% |
| Q1 2025 | $156.1M | -13% |
| Q4 2024 | $977.8M | +$2.4B |
LLY has the edge over LAB on cash generation, producing positive trailing cash flow while its opponent burns cash.
LAB Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | +0.7% | +2.7M shares |
| 1 year | +2.9% | +10.9M shares |
| 3 years | +397% | +314M shares |
| 5 years | +416% | +317M shares |
| Available history | +489% | +327M shares |
LAB has 394M diluted shares, up 2.9% from a year ago.
| Quarter | Spent |
|---|---|
| Q4 2025 | — |
| Q3 2025 | — |
| Q2 2025 | — |
| Q1 2025 | — |
| Q4 2024 | — |
| Q3 2024 | — |
| Q2 2024 | $29.4M |
| Q1 2024 | $11.1M |
LLY Total Shares
| Period | Change % | Net change |
|---|---|---|
| Quarterly | 0% | -300K shares |
| 1 year | -0.6% | -5.4M shares |
| 3 years | -0.7% | -6.4M shares |
| 5 years | -1.9% | -17.4M shares |
| Available history | -4.5% | -42.3M shares |
LLY has the edge over LAB on shareholder dilution, with a more favorable share count trend.
| Quarter | Spent |
|---|---|
| Q3 2026 | $377M |
| Q2 2026 | $1.6B |
| Q1 2026 | $2.4B |
| Q4 2025 | $1.5B |
| Q3 2025 | $708.1M |
| Q2 2025 | $692.2M |
| Q1 2025 | $1.2B |
| Q4 2024 | $2.1B |
LLY spent $5.8B buying back its own shares over the past year, up 26% from the year before.
LAB Net Leverage
LLY Net Leverage
| Quarter | Net Leverage | Status |
|---|---|---|
| Q3 2026 | 1.2x | Healthy |
| Q2 2026 | 1.3x | Healthy |
| Q1 2026 | 1.2x | Healthy |
| Q4 2025 | 1.3x | Healthy |
| Q3 2025 | 1.3x | Healthy |
| Q2 2025 | 2.0x | Healthy |
| Q1 2025 | 2.3x | Moderate |
| Q4 2024 | 2.1x | Moderate |
LLY's net debt is about 1.2 years of its operating earnings (EBITDA), about the same as a year ago.
LAB Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 39.4 | Neutral |
| Stochastic | 16.7 | Oversold |
LAB's weekly RSI is 39 (neutral) and its Stochastic is 17 (oversold).
LLY Weekly Momentum
| Metric | Value | Status |
|---|---|---|
| RSI | 68.3 | Neutral |
| Stochastic | 84.1 | Overbought |
LLY's weekly RSI is 68 (neutral) and its Stochastic is 84 (overbought).
LAB PE vs Healthcare Sector
| Metric | LAB | Sector median | Relative |
|---|---|---|---|
| PE | 1.9x | 26x | 93% below |
| PE % | 4 | 29 | 25 pts below |
LAB has the edge over LLY on valuation relative to its sector.
LLY PE vs Healthcare Sector
| Metric | LLY | Sector median | Relative |
|---|---|---|---|
| PE | 46x | 26x | 79% above |
| PE % | 48 | 29 | 19 pts above |
LLY is trading at 46x earnings, a 79% premium to the Healthcare sector's median of 26x.
LAB Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $0.66 | 1.5% below |
| 20 week MA | $0.74 | 12% below |
| 50 week MA | $0.97 | 33% below |
| 100 week MA | $1.14 | 43% below |
| 200 week MA | $1.66 | 61% below |
LAB is in a downtrend: it's below all five of its weekly moving averages, and 61% below its 200-week average.
LLY Weekly Moving Averages
| Moving average | MA price | Relative |
|---|---|---|
| 8 week MA | $1,279.4 | 12% above |
| 20 week MA | $1,218.8 | 17% above |
| 50 week MA | $1,102.2 | 29% above |
| 100 week MA | $954.1 | 50% above |
| 200 week MA | $797.5 | 79% above |
LLY has the edge over LAB on trend strength, trading above more of its moving averages.
LAB Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $3.36 | $6.48 | +93% |
| 2021 | $6.48 | $3.80 | -41% |
| 2022 | $3.80 | $1.35 | -64% |
| 2023 | $1.35 | $2.21 | +64% |
| 2024 | $2.21 | $1.82 | -18% |
| 2025 | $1.82 | $1.38 | -24% |
| 2026 YTD | $1.38 | $0.65 | -53% |
LAB has finished lower in four of the last six years. It's down 53% so far in 2026.
LLY Yearly ROI
| Year | Start price | End price | ROI |
|---|---|---|---|
| 2020 | $131.5 | $166.7 | +27% |
| 2021 | $166.7 | $273.1 | +64% |
| 2022 | $273.1 | $367.9 | +35% |
| 2023 | $367.9 | $582.9 | +58% |
| 2024 | $582.9 | $783.2 | +34% |
| 2025 | $783.2 | $1,077.8 | +38% |
| 2026 YTD | $1,077.8 | $1,427.3 | +32% |
LLY has the edge over LAB on returns for 2026, with the stronger performance.